Key takeawaysResearchers and scientists have engineered a new class of supercharged T cells that are stronger, longer-lasting ...
Zacks Investment Research on MSN
PFE Talzenna combo shows strong efficacy in wider prostate cancer use
Pfizer PFE reported positive top-line results from a late-stage study evaluating Talzenna (talazoparib), an oral PARP inhibitor, in combination with Xtandi (enzalutamide), an ARP inhibitor. The ...
UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, ...
Pfizer Inc. PFE shares are up during Thursday’s trading session after the company shared data from Talzenna plus Xtandi’s investigational treatment regimen for HRR gene-mutated metastatic ...
By Tim BakerClose readers of this blog and, indeed, the PCFA website, may have picked up on the carefully guarded secret that I have written a book ...
Dr Amir Khan, who regularly provides health guidance across social media platforms and daytime television, works as an NHS GP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results